Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2012 | Image of the Month

[⁶⁸Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with ¹⁸F-FECH

Authors: A. Afshar-Oromieh, U. Haberkorn, M. Eder, M. Eisenhut, CM. Zechmann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2012

Excerpt

Prostate-specific membrane antigen (PSMA) is a cell surface protein, which is expressed at higher levels in prostate cancer compared to other tissues. This protein provides a promising target for specific imaging and therapy due to its transmembrane location and internalization after ligand binding [1]. PSMA is also expressed in the neovasculature of many solid tumours [2, 3]. Recently procedures have been developed to label PSMA with ⁶⁸Ga and ¹²⁴I for positron emission tomography (PET) imaging [4, 5]. …

Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528–39.PubMedCrossRef

Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674–81.PubMed

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192–8.PubMed

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69(17):6932–40.PubMedCrossRef

Eder M, Schäfer M, Bauder-Wüst U, Wängler C, Mier W, Haberkorn U, Eisenhut M. The ⁶⁸Ga-complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjug Chem 2011, in revision.

Title: [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
Authors: A. Afshar-Oromieh
U. Haberkorn
M. Eder
M. Eisenhut
CM. Zechmann
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2069-0

At a glance: The STEP trials

Springer Medicine

[⁶⁸Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with ¹⁸F-FECH

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2012

FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET

Impact of a new ultrafast CZT SPECT camera for myocardial perfusion imaging: fewer equivocal results and lower radiation dose

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer

Comment on Reyes et al.: Myocardial perfusion scintigraphy in Europe 2007: a survey of the European Council of Nuclear Cardiology

Quantification of myocardial blood flow with 82Rb positron emission tomography: clinical validation with 15O-water